Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Overweight and Obesity Clinical Trial

Official title:

Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05316493
• Other study ID #: 53211036-02
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: June 13, 2022
• Est. completion date: February 28, 2026

Study information

• Verified date: May 2023
• Source: Fudan University
• Contact: WEIWEI SHAN, PhD
• Phone: 8613817813106
• Email: danweiwei7468[@]fckyy.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

Description:

Background:

High-efficacy progesterone, such as levonorgestrel intrauterine system (LNG-IUS), megestrol acetate (MA), and medroxyprogesterone acetate(MPA), is the first-line treatment for women with endometrial atypical hyperplasia (EAH) who want to preserve fertility. About 70% to 80% of those patients can achieve complete remission (CR) with a median CR time of about 6 months, but about 20% to 30% of those patients get no response or need longer time to get CR (over one year or even longer).

Overweight or obesity is an independent risk factor for fertility-sparing treatment response and pregnancy outcomes in young females with EAH or early endometrioid cancer (EEC). Evidence showed that obesity can cause lower CR rates and longer time to get CR and lower birth rates in EAH or EEC patients asking for conservative therapy. Weight management has been proved to improve metabolic disorders, ovarian functions, and pregnancy outcomes. Metformin, as a diabetes drug, has been proved to increase CR rates in EAH or EEC patients treated with MA for fertility. Weight management has raised more and more attention and has been proved to benefit metabolic and pregnancy outcomes. Based on previous research and published studies, the hypothesise is that weight management plus progestin therapy may raise CR rates and pregnancy outcomes in young female EAH patients asking for fertility conservation.

Enhanced lifestyle management (diet control, exercise, and daily behavioral guidance) may improve metabolic conditions, increase CR rates and pregnancy outcomes in obese EAH patients who want to preserve fertility. Till now, no similar studies were found, so this study is designed to explore the efficacy of weight control in EAH fertility-sparing patients to provide new evidence for improving conservative treatment.

Objective:

To investigate whether weight management plus LNG-IUS/MA can improve the efficacy of preserving fertility in obese EAH women who want fertility conservation.

Design:

This study is designed according to Simon's Two-Stage Design. Based on BMI and treatment plans, four single-arms are designed. This study is prospective, open-label. EAH Patients requiring conservation treatment with BMI ≥ 24 kg/m2 will be recruited in this study and they will be divided into four arms, the first group recruits overweight (24kg/ m2≤BMI<28kg/m2) patients treated with LNG-IUS, the second group recruits overweight (24kg/ m2≤BMI<28kg/m2) patients treated with MA, the third group recruits obese (BMI≥28kg/m2) patients treated with LNG-IUS, and the last group recruits obese (BMI≥28kg/m2) patients treated with MA. The sample size is calculated based on Simon's Two-Stage Design and previous CR rates. All enrolled patients will receive enhanced lifestyle management to control weight and take LNG-IUS/MA for treating EAH. Hysteroscopic examination, metabolic and inflammatory indicators will be performed every 12 to16 weeks while other indexes will be evaluated every month, including weight, heart rates, blood pressure, body fat tests, and so on. For the progestin efficacy evaluation, CR is defined as the remission of EAH to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease, and progressive disease (PD) is defined as disease progression in patients. Two months' maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.

Outcomes: Primary outcome is the CR rates of the four arms. Secondary outcomes include pregnancy rates, live birth rates, weight loss, insulin resistance, chronic inflammation indicators, time to achieve CR and recurrence rates, and so on. Safety and side events during the whole trial will be monitored in two years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 172
• Est. completion date: February 28, 2026
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1.18 years=age=45years 2.BMI (body mass index) =24kg/m2 3.Consent informed and signed 4.Pathologically confirmed as endometrial atypical hyperplasia. Patients with endometrial specimens obtained by endometrial biopsy, diagnostic curettage or hysteroscopy and diagnosed histologically as endometrial atypical hyperplasia. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.

5.Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.

6.Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.

Exclusion Criteria:

1. Combined with severe medical disease or liver or kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level elevates to 3 times or more of the upper limit of normal, kidney dysfunction (creatinine clearance < 30 mL/min)

2. Patients are diagnosed with other malignant tumors of the reproductive system; patients with breast cancer or other hormone-dependent tumors that cannot be used with progesterone.

3. Those who have received high doses of high potency progestin or oral contraceptives within the last 3 months (or those on maintenance medication).

4. Those who require hysterectomy or other methods other than conservative treatment.

5. Known or suspected pregnancy.

6. Those who has contraindications to use progestin.

7. Deep vein thrombosis, stroke, myocardial infarction.

8. Severe joint lesions that prevent walking or movement.

9. untreated or recurrent pelvic inflammatory disease (PID)

10. an untreated or uncontrolled pelvic infection (vaginal, cervical, uterine);

11. Cervical dysplasia

12. Congenital or acquired uterine abnormalities, including uterine fibroid tumors or conditions that affect the shape of the uterus

13. allergic to the LNG-IUS components

14. uterine cavity is too large (average uterine diameter is over 7 cm) or have a history of LNG-IUS falling out.

Notes: the last 6 criteria are only applied for patients with LNG-IUS.

Related Conditions & MeSH terms

• Atypical Endometrial Hyperplasia
• Endometrial Hyperplasia
• Fertility Issues
• Hyperplasia
• Infertility
• Overweight
• Overweight and Obesity

Intervention

Behavioral:
• Intensive Lifestyle Intervention (ILI)
dietary guidance, exercise guidance, lifestyle intervention

Drug:
• Megestrol Acetate 160 MG Oral Tablet
enrolled participants will take Megestrol Acetate 160mg daily
• Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
enrolled patients will be treated with LNG-IUS.

Locations

Country	Name	City	State
China	Obstetrics and Gynecology Hospital of Fudan University	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xiaojun Chen

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response (CR) rates	The 28-week CR rates will be calculated in four arms	From date of recruitment until the date of CR, assessed up to 28 weeks.
Secondary	Pregnancy outcomes	For participants have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period.	up to 2 years after complete response of the last participant
Secondary	Weight change	The investigators will record body weight every month and calculate its change in kilograms.	From date of recruitment, assessed up to 28 weeks.
Secondary	Body composition change	The investigators will detect body composition with InBody machine and calculate changes of the indicated indexes.	From date of recruitment, assessed up to 28 weeks.
Secondary	Blood pressures change	Record blood pressures (systolic and diastolic pressures) every 12-16 weeks and count the change during the trial.	From date of recruitment, assessed up to 28 weeks.
Secondary	Heart rates change	Record heart rates (beats per minute) every 12-16 weeks and count the change.	From date of recruitment, assessed up to 28 weeks.
Secondary	Blood glucose change	Assess fasting glucose levels each 3 to 4 months and calculate changes in mmol/L.	From date of recruitment, assessed up to 28 weeks.
Secondary	Blood lipids change	Assess blood lipids levels each 3 to 4 months and calculate changes during the trial.	From date of recruitment, assessed up to 28 weeks.
Secondary	Insulin resistance change	Test fasting insulin levels each 3 to 4 months, and count HOMA-IR index (Homeostatic Model Assessment for Insulin Resistance) with fasting insulin and fasting glucose as follow: Insulin (pmol/L)*glucose (mmol/L)/22.5, and compare the HOMA-IR change during the treatment.	Baseline,3months and 6months after enrolled.
Secondary	Ovarian reserve function	Detect serum Anti-Mullerian Hormone (AMH) each 3 or 4 months and calculate its change.	From date of recruitment, assessed up to 28 weeks.
Secondary	Quality of life change	Collect the questionnaire SF-36 and count scores change through conservative treatment.	From date of recruitment, assessed up to 28 weeks.
Secondary	Impact of Weight on Quality of Life	Collect questionnaire IWQOL- LITE and count scores change through conservative treatment.	From date of recruitment, assessed up to 28 weeks.
Secondary	Physical activities change	Collect physical activities questionnaire(IPAQ) and compare scores changes through conservative treatment.	From date of recruitment, assessed up to 28 weeks.
Secondary	Chronic inflammatory index (TNF-a) change	The investigators will detect the levels of TNF-a (fmol/ml) in serum and calculate changes through the whole treatment period.	baseline, 3 months and 6 months after treatment.
Secondary	Chronic inflammatory index (IL-1) change	The investigators will detect serum index IL-1 in U/ml and calculate changes through the whole treatment period.	baseline, 3 months and 6 months after treatment.
Secondary	Chronic inflammatory index (IL-6) change	The investigators will detect serum index IL-6 in U/ml and calculate changes through the whole treatment period.	baseline, 3 months and 6 months after treatment.
Secondary	Time of pathological complete response (CR)	Time of histologic regression from EAH to proliferative or secretory endometrium	From date of recruitment until the date of CR, assessed up to 2 years.
Secondary	Incidence of adverse events	Adverse events related with MA, LNG-IUS and weight control. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.	From date of recruitment until the date of CR, assessed up to 2 years.
Secondary	Relapse rates	All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then the investigators can get the relapse rates.	up to 2 years after the treatment for each patient